Advantage Alpha Capital Partners LP Takes Position in Certara, Inc. (NASDAQ:CERT)

Advantage Alpha Capital Partners LP purchased a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 160,156 shares of the company's stock, valued at approximately $1,875,000. Advantage Alpha Capital Partners LP owned approximately 0.10% of Certara as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Brown Brothers Harriman & Co. purchased a new stake in Certara during the 3rd quarter worth approximately $27,292,000. Massachusetts Financial Services Co. MA grew its holdings in shares of Certara by 40.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company's stock valued at $45,691,000 after buying an additional 1,128,006 shares during the last quarter. Daventry Group LP increased its position in shares of Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company's stock valued at $18,124,000 after acquiring an additional 791,405 shares during the period. Kopion Asset Management LLC purchased a new position in Certara in the 3rd quarter worth $4,457,000. Finally, Sei Investments Co. lifted its position in Certara by 39.5% during the second quarter. Sei Investments Co. now owns 997,871 shares of the company's stock valued at $13,821,000 after purchasing an additional 282,357 shares during the period. Hedge funds and other institutional investors own 73.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CERT. Barclays dropped their target price on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a report on Thursday, November 7th. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Finally, Robert W. Baird cut their price objective on shares of Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $15.92.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now owns 99,704 shares of the company's stock, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares of the company's stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by insiders.

Certara Price Performance

Shares of NASDAQ CERT traded down $0.12 during trading on Tuesday, hitting $10.93. The company had a trading volume of 1,003,471 shares, compared to its average volume of 802,369. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -55.25, a price-to-earnings-growth ratio of 5.24 and a beta of 1.51. The stock has a fifty day simple moving average of $10.80 and a two-hundred day simple moving average of $13.13. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a fifty-two week low of $9.41 and a fifty-two week high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara's quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.06 EPS. On average, research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.